518 related articles for article (PubMed ID: 35842740)
1. Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Sprenger-Svačina A; Klein I; Wüstenberg H; Kohle F; Schneider C; Grether NB; Wunderlich G; Fink GR; Klein F; Di Cristanziano V; Lehmann HC
Eur J Neurol; 2022 Nov; 29(11):3380-3388. PubMed ID: 35842740
[TBL] [Abstract][Full Text] [Related]
2. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
4. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
5. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
[No Abstract] [Full Text] [Related]
6. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
Front Immunol; 2022; 13():892331. PubMed ID: 36003404
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
9. Antibody response of smokers to the COVID-19 vaccination: Evaluation based on cigarette dependence.
Mori Y; Tanaka M; Kozai H; Hotta K; Aoyama Y; Shigeno Y; Aoike M; Kawamura H; Tsurudome M; Ito M
Drug Discov Ther; 2022 May; 16(2):78-84. PubMed ID: 35370256
[TBL] [Abstract][Full Text] [Related]
10. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
13. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines.
Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA
Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108
[No Abstract] [Full Text] [Related]
14. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads.
Golan Y; Prahl M; Cassidy AG; Gay C; Wu AHB; Jigmeddagva U; Lin CY; Gonzalez VJ; Basilio E; Chidboy MA; Warrier L; Buarpung S; Li L; Murtha AP; Asiodu IV; Ahituv N; Flaherman VJ; Gaw SL
Front Immunol; 2021; 12():777103. PubMed ID: 34804068
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
[TBL] [Abstract][Full Text] [Related]
17. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
Dalakas MC; Bitzogli K; Alexopoulos H
Front Immunol; 2021; 12():627285. PubMed ID: 33679770
[No Abstract] [Full Text] [Related]
19. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
